Company intelligence / Profile preview

BRIM Biotechnology, Inc.

Ownership: Private
Employees: ~32
Development stage: Phase 3

Overview

Lead asset BRM421 for Dry Eye Disease is in Phase 3 clinical trials. BRM424 for neurotrophic keratitis has received FDA Orphan Drug Designation and is in Phase 2 trials. The company's regenerative peptides have shown neurotrophic effects and can activate stem cells to repair damaged tissues.

Therapeutic areas: OphthalmologyRheumatology
Modalities: Regenerative peptides
Industry: Biotech

Drug pipeline

7 assets

BRM421

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on BRIM Biotechnology, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRIM Biotechnology, Inc..

Explore the full profile